Cancer
Conditions
Keywords
Cancer
Brief summary
This study is being done to determine the highest safe dose of the combination of temsirolimus and axitinib; to learn the side effects when these drugs are given together; and to determine how the patient's disease responds to treatment. The combination of the drugs temsirolimus and axitinib has not been studied before so it is unknown whether this treatment will have any benefit in the patient's cancer. Temsirolimus is commercially available and approved for treatment of some types of kidney cancer. Axitinib has been tested in several diseases but it is not yet commercially available for the treatment of any cancer in the United States. The combination of temsirolimus and axitinib is not approved for treatment of any cancer outside of a clinical trial.
Interventions
DRUGAxitinib
Combination treatment with temsirolimus and axitinib
DRUGTemsirolimus
Combination treatment with temsirolimus and axitinib
Sponsors
Pfizer
Emory University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
/
Exclusion criteria
* Patients must have histologically confirmed non-hematologic malignancy for which standard curative or palliative measures do not exist or are no longer effective * Patients with hepatocellular carcinoma do not need histologic confirmation of malignancy if the following criteria were met at diagnosis: * Liver lesions 1 - 2 cm with arterial enhancement and washout in venous phase of CT/MRI * Liver lesions ≥ 2 cm with arterial enhancement and washout in venous phase of CT/MRI or serum alpha-feto protein ≥ 200 ng/mL * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Marrow and Organ function requirements: * Absolute Neutrophil Count ≥ 1000/mm³ * Platelets ≥ 75,000/mm³ * Hemoglobin ≥ 9.0 g/dL * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) * Alkaline phosphatase ≤ 2.5 x ULN (≤ 5 x ULN if liver metastasis present) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN if liver metastasis present or patient has diagnosis of hepatocellular carcinoma or cholangiocarcinoma) * Creatinine ≤ 1.5 x ULN * Urinalysis ≤ 1+ protein on dipstick or Urine creatinine:protein ratio \< 1.0 If urine protein \>1 1+ or urine creatinine:protein ratio \> 1, then 24 hour urine protein should be obtained and the level should be \< 1000 mg for patient enrollment. * Fasting serum cholesterol ≤ 350 mg/dL * Triglycerides ≤1.5 x ULN * Life expectancy ≥ 12 weeks * At least 2 weeks since end of prior systemic treatment (4 weeks for bevacizumab containing regimens), radiotherapy, or surgical procedure with resolution of all treatment related toxicity * No evidence of uncontrolled hypertension as evidenced by 2 readings of \< 140/90 measured 1 hour apart. Preexisting hypertension controlled with medication is allowed * No gastrointestinal disorders including active peptic ulcer disease (within 6 months); active bleeding unrelated to malignancy; or melena, hematemesis, or hematochezia in the past 3 months without endoscopically-proven resolution * No cardiovascular history within 12 months including: myocardial infarction (MI), uncontrolled angina, coronary artery bypass graft (CABG), or symptomatic congestive heart failure (CHF) * Women of child bearing potential must have negative pregnancy test * Willingness and ability to comply with scheduled visits * Able to ingest oral medications * No concurrent use or anticipated need for potent cytochrome P450 3A4 (CYP3A4) inhibitors or CYP3A4 or cytochrome P450 1A2 (CYP1A2) inducers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for evaluation. | Approximately re-evaluated every 8 weeks | Complete Response: Disappearance of all target lesions.Any pathological lymph nodes must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions.Note: the appearance of one or more new lesions is also considered progressions). Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. |
Countries
United States
Outcome results
None listed